Acadian Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Acadian Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10K	Sell	721 -18,367	-96%	-$409K	﹤0.01%	1979
2025 Q4	$477K	Buy	+19,088	New	+$340K	﹤0.01%	1317
2024 Q2	–	Sell	-103,179	Closed	-$1.17M	–	1869
2024 Q1	$1.17M	Sell	103,179 -152,746	-60%	-$1.97M	﹤0.01%	802
2023 Q4	$3.59M	Sell	255,925 -236,956	-48%	-$3.18M	0.01%	536
2023 Q3	$6.08M	Sell	492,881 -86,428	-15%	-$881K	0.03%	384
2023 Q2	$5.23M	Buy	579,309 +3,409	+0.6%	+$20.6K	0.02%	449
2023 Q1	$2M	Hold	575,900	–	–	0.01%	715
2022 Q4	$1.41M	Buy	575,900 +2,923	+0.5%	+$8.53K	0.01%	761
2022 Q3	$1.58M	Buy	572,977 +106,811	+23%	+$453K	0.01%	695
2022 Q2	$1.9M	Buy	466,166 +351,090	+305%	+$1.11M	0.01%	649
2022 Q1	$489K	Buy	115,076 +14,454	+14%	+$79.7K	﹤0.01%	1007
2021 Q4	$940K	Buy	+100,622	New	+$2.08M	﹤0.01%	850

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Acadian Asset Management's OLMA Position: Q1 2026 in Review

Acadian Asset Management reduced its Olema Pharmaceuticals (OLMA) stake by 96% in Q1 2026, selling an estimated $409K and leaving 721 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

Acadian Asset Management first reported a position in OLMA in Q4 2021 and has held it in 12 quarters since. The position peaked at $6.08M in Q3 2023. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

Acadian Asset Management held 721 shares of Olema Pharmaceuticals worth $10K as of Q1 2026.
Acadian Asset Management sold 18,367 Olema Pharmaceuticals shares in Q1 2026, an estimated $409K.
Olema Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1979 holding.
Acadian Asset Management first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Acadian Asset Management's Olema Pharmaceuticals position peaked at $6.08M in Q3 2023.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.